<DOC>
	<DOCNO>NCT02400216</DOCNO>
	<brief_summary>Background : - Hepatitis C infection ( HCV ) lead cause liver disease . Normal bacteria intestine may spread liver blood liver disease . This call bacterial translocation ( BT ) . Researchers think BT may cause liver disease worsen . Objectives : - To study mechanism involve BT early advance liver disease . To find whether BT cause liver disease worsen . Eligibility : - People age 18 HCV clinically stable liver disease . Design : - Participants screen medical history physical exam . They blood test image study . - Participants 2 outpatient visit 3-day stay clinic . - At visit 1 , participant urine blood test . They magnetic resonance imaging ( MRI ) scan . A solution inject vein . The MRI scanner metal cylinder surround magnetic field . The participant lie table slide cylinder . - At visit 2 , substance inject vein swallow . Participants blood drawn 5 time 90 minute . - During inpatient stay , serial blood test draw . - Participants give 2 stool sample another MRI . - A needle insert chest wall vein inside liver , guide ultrasound . The blood pressure inside vein measure blood drawn . About 1 inch liver tissue remove . - A study investigator call participant discuss test result .</brief_summary>
	<brief_title>Deciphering Mechanisms Involved Microbial Translocation Across Spectrum HCV Associated Liver Fibrosis</brief_title>
	<detailed_description>Hepatitis C ( HCV ) lead cause cirrhosis worldwide . Most complication associate cirrhosis drive alter portal circulation development portal hypertension . Bacterial translocation ( BT ) gut systemic circulation consider pivotal mechanism contribute development life-threatening complication end stage cirrhosis . Recent evidence suggest liver systemic circulation may expose gut derive microbial product earlier stage liver disease . This early exposure may trigger hepatic inflammation , modify immune host response accelerate hepatic fibrogenesis ; , turn , impairs portal inflow , alters portal circulation , lead development portal hypertension . The mechanisms result systemic exposure gut derive microbial product , subsequent host response BT study patient early liver disease fully compensate cirrhosis . We therefore intend enroll 30 chronic HCV patient either cirrhosis ( 20 ) minimal liver fibrosis ( 10 ) . Study participant undergo extensive evaluation portal vein sample pressure measurement , dual cholate clearance , liver biopsy , serologic , immunologic , fecal microbiome imaging study . This follow optional second percutaneous liver biopsy portal vein sample 9-15 month HCV treatment . The treatment protocol separate independent protocol , 15-DK- 0143 utilizing Sofosbuvir GS-5816 . The goal study characterize extent BT early stage cirrhotic non-cirrhotic liver disease , explore mechanisms contribute occurrence identify potential serological , immunological hemodynamic biomarkers associate chronic infection . This , turn , aid establish possible link BT , subsequent host response severity liver disease .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . All age great 18 male female 2 . Capacity provide write informed consent 3 . Evidence HCV RNA 2 serum sample least 6 month apart . 4 . All HCV genotype 5 . Liver biopsy last 2 year prior enrollment show Ishak fibrosis score either 01 56 . An alternative liver biopsy Fibroscan study perform 6 month prior study enrollment show score either kPa &lt; 7 13 . 6 . ChildPugh score less equal 6 7 . Prior liver biopsy portal vein cannulation procedure , blood drawn CBC , PT/INR &amp; acute care panel . EXCLUSION CRITERIA : 1 . Pregnant woman females child bearing age take measure prevent pregnancy period study 2 . Patients currently treatment hepatitis C 3 . Clinical , serologic histopathologic evidence support etiology chronic liver disease besides HCV 4 . Current past clinical evidence decompensated liver disease ( e.g . ascites , bleed esophageal varix , spontaneous bacterial peritonitis , encephalopathy etc . ) 5 . Cross sectional liver imaging study past 6 month show focal lesion suspicious hepatocellular carcinoma and/or alphafetoprotein level great 200 ng/mL . 6 . Patients active bacterial , viral fungal , systemic localized infection . 7 . Antibiotic treatment 30 day prior study enrollment 8 . History chronic inflammatory disease bowel ( Crohn disease , Ulcerative colitis celiac disease ) 9 . History congestive heart failure moderate severe degree . 10 . History noncirrhotic portal hypertension portal vein thrombosis 11 . Patients severe allergic reaction iodine contrast , control premedication antihistamine steroid . 12 . EXCLUSION CRITERIA FOR MRI : 12.1 Subjects contraindication MRI scanning . These contraindication include limited following device condition : &lt; TAB &gt; . Implanted cardiac pacemaker defibrillator &lt; TAB &gt; b . Cochlear Implants &lt; TAB &gt; c . Ocular foreign body ( e.g . metal shaving ) &lt; TAB &gt; . Embedded shrapnel fragment &lt; TAB &gt; e . Central nervous system aneurysm clip &lt; TAB &gt; f . Implanted neural stimulator &lt; TAB &gt; g . Medical infusion pump &lt; TAB &gt; h . Any implanted device incompatible MRI . 12.2 Unsatisfactory performance status judge refer physician subject could tolerate MRI scan . Examples medical condition would accept would include unstable angina dyspnea rest . 12.3 Subjects require sedation MRI study . 12.4 Subjects condition preclude entry scanner ( e.g . morbid obesity , claustrophobia , etc. ) . 12.5 Pregnant lactate woman . 12.6 Subjects severe backpain motion disorder unable tolerate supine position within MRI scanner hold still duration examination . 12.7 For Gadolinium base SPIO MRI Use : &lt; TAB &gt; . History severe allergic reaction contrast agent despite use premeditation antihistaminic cortisone . &lt; TAB &gt; b . eGFR &lt; 60 ml/min/1.73m^2 13 . Absolute neutrophil count 1000/mm^3 , Hemoglobin level 10.0 g/dl platelet count low 70,000/mm^3 . 14 . INR great equal 1.5 , PTT great equal 1.3 time control and/or know history disease associate increase bleed diathesis . 15 . Serum creatinine great equal 2.0 mg/dl unless measure creatinine clearance great 60 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 3, 2017</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Liver Biopsy</keyword>
	<keyword>Microbiome</keyword>
</DOC>